Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.
Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) exhibit single-agent activity in colorectal cancer, have nonoverlapping major toxicities, and exhibit a synergistic effect in tumor xenograft models. European early-phase trials of the combination in patients with metastatic colorectal cancer...
| Main Author: | |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2002
|
| _version_ | 1797057069024542720 |
|---|---|
| author | Kerr, D |
| author_facet | Kerr, D |
| author_sort | Kerr, D |
| collection | OXFORD |
| description | Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) exhibit single-agent activity in colorectal cancer, have nonoverlapping major toxicities, and exhibit a synergistic effect in tumor xenograft models. European early-phase trials of the combination in patients with metastatic colorectal cancer indicate good response rates across doses tested and manageable toxicities, with available data supporting use of a regimen of oral capecitabine at 1,000 mg/m2 twice daily on days 1 to 14 plus IV irinotecan at 250 mg/m2 on day 1 every 21 days in this setting. The European Organisation for Research and Treatment of Cancer has planned a phase III trial (EORTC 40015) comparing this regimen of capecitabine/irinotecan with infusional fluorouracil (5-FU)/leucovorin plus irinotecan in approximately 700 patients with metastatic colorectal cancer. The QUASAR (Quick and Simple and Reliable) 2 adjuvant trial will compare 5-FU/leucovorin with capecitabine/irinotecan given over 6 months as adjuvant therapy in patients with stage II/III colorectal cancer. These trials will help define the roles of this combination in the treatment of colorectal cancer. |
| first_indexed | 2024-03-06T19:31:04Z |
| format | Journal article |
| id | oxford-uuid:1d7b27e9-f4ed-42d6-af6d-f27b911a3bb3 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:31:04Z |
| publishDate | 2002 |
| record_format | dspace |
| spelling | oxford-uuid:1d7b27e9-f4ed-42d6-af6d-f27b911a3bb32022-03-26T11:11:00ZCapecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:1d7b27e9-f4ed-42d6-af6d-f27b911a3bb3EnglishSymplectic Elements at Oxford2002Kerr, DCapecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) exhibit single-agent activity in colorectal cancer, have nonoverlapping major toxicities, and exhibit a synergistic effect in tumor xenograft models. European early-phase trials of the combination in patients with metastatic colorectal cancer indicate good response rates across doses tested and manageable toxicities, with available data supporting use of a regimen of oral capecitabine at 1,000 mg/m2 twice daily on days 1 to 14 plus IV irinotecan at 250 mg/m2 on day 1 every 21 days in this setting. The European Organisation for Research and Treatment of Cancer has planned a phase III trial (EORTC 40015) comparing this regimen of capecitabine/irinotecan with infusional fluorouracil (5-FU)/leucovorin plus irinotecan in approximately 700 patients with metastatic colorectal cancer. The QUASAR (Quick and Simple and Reliable) 2 adjuvant trial will compare 5-FU/leucovorin with capecitabine/irinotecan given over 6 months as adjuvant therapy in patients with stage II/III colorectal cancer. These trials will help define the roles of this combination in the treatment of colorectal cancer. |
| spellingShingle | Kerr, D Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. |
| title | Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. |
| title_full | Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. |
| title_fullStr | Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. |
| title_full_unstemmed | Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. |
| title_short | Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. |
| title_sort | capecitabine irinotecan in colorectal cancer european early phase data and planned trials |
| work_keys_str_mv | AT kerrd capecitabineirinotecanincolorectalcancereuropeanearlyphasedataandplannedtrials |